nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.00301	0.00374	CcSEcCtD
Midodrine—Urethral disorder—Gemcitabine—pancreatic cancer	0.00299	0.00371	CcSEcCtD
Midodrine—Flushing—Irinotecan—pancreatic cancer	0.00291	0.00361	CcSEcCtD
Midodrine—Cardiac disorder—Irinotecan—pancreatic cancer	0.00291	0.00361	CcSEcCtD
Midodrine—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00288	0.00358	CcSEcCtD
Midodrine—Dry skin—Docetaxel—pancreatic cancer	0.00287	0.00356	CcSEcCtD
Midodrine—Hypertension—Sunitinib—pancreatic cancer	0.00286	0.00355	CcSEcCtD
Midodrine—Insomnia—Tamoxifen—pancreatic cancer	0.00285	0.00354	CcSEcCtD
Midodrine—Angiopathy—Irinotecan—pancreatic cancer	0.00284	0.00353	CcSEcCtD
Midodrine—Paraesthesia—Tamoxifen—pancreatic cancer	0.00283	0.00352	CcSEcCtD
Midodrine—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00283	0.00352	CcSEcCtD
Midodrine—Insomnia—Erlotinib—pancreatic cancer	0.00282	0.0035	CcSEcCtD
Midodrine—Dyspnoea—Tamoxifen—pancreatic cancer	0.00281	0.00349	CcSEcCtD
Midodrine—Chills—Irinotecan—pancreatic cancer	0.00281	0.00349	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.0028	0.00347	CcSEcCtD
Midodrine—Dyspnoea—Erlotinib—pancreatic cancer	0.00278	0.00345	CcSEcCtD
Midodrine—Dyspepsia—Tamoxifen—pancreatic cancer	0.00277	0.00345	CcSEcCtD
Midodrine—Angiopathy—Gemcitabine—pancreatic cancer	0.00277	0.00344	CcSEcCtD
Midodrine—Dry mouth—Sunitinib—pancreatic cancer	0.00275	0.00342	CcSEcCtD
Midodrine—Dyspepsia—Erlotinib—pancreatic cancer	0.00275	0.00341	CcSEcCtD
Midodrine—Chills—Gemcitabine—pancreatic cancer	0.00274	0.0034	CcSEcCtD
Midodrine—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00272	0.00338	CcSEcCtD
Midodrine—Pain—Tamoxifen—pancreatic cancer	0.0027	0.00335	CcSEcCtD
Midodrine—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00269	0.00334	CcSEcCtD
Midodrine—Flatulence—Irinotecan—pancreatic cancer	0.00269	0.00334	CcSEcCtD
Midodrine—Cramps of lower extremities—Epirubicin—pancreatic cancer	0.00267	0.00332	CcSEcCtD
Midodrine—Pain—Erlotinib—pancreatic cancer	0.00267	0.00331	CcSEcCtD
Midodrine—Nervous system disorder—Sunitinib—pancreatic cancer	0.00265	0.00329	CcSEcCtD
Midodrine—Back pain—Irinotecan—pancreatic cancer	0.00264	0.00327	CcSEcCtD
Midodrine—Skin disorder—Sunitinib—pancreatic cancer	0.00262	0.00326	CcSEcCtD
Midodrine—Muscle spasms—Irinotecan—pancreatic cancer	0.00262	0.00325	CcSEcCtD
Midodrine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00258	0.0032	CcSEcCtD
Midodrine—Back pain—Gemcitabine—pancreatic cancer	0.00257	0.00319	CcSEcCtD
Midodrine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00255	0.00317	CcSEcCtD
Midodrine—Abdominal pain—Tamoxifen—pancreatic cancer	0.00249	0.0031	CcSEcCtD
Midodrine—Cramps of lower extremities—Doxorubicin—pancreatic cancer	0.00247	0.00307	CcSEcCtD
Midodrine—Abdominal pain—Erlotinib—pancreatic cancer	0.00247	0.00306	CcSEcCtD
Midodrine—Insomnia—Sunitinib—pancreatic cancer	0.00244	0.00303	CcSEcCtD
Midodrine—Paraesthesia—Sunitinib—pancreatic cancer	0.00242	0.00301	CcSEcCtD
Midodrine—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.00241	0.003	CcSEcCtD
Midodrine—Dyspnoea—Sunitinib—pancreatic cancer	0.00241	0.00299	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00239	0.00297	CcSEcCtD
Midodrine—Dyspepsia—Sunitinib—pancreatic cancer	0.00238	0.00295	CcSEcCtD
Midodrine—Hypertension—Irinotecan—pancreatic cancer	0.00235	0.00292	CcSEcCtD
Midodrine—Stomatitis—Docetaxel—pancreatic cancer	0.00235	0.00292	CcSEcCtD
Midodrine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00233	0.0029	CcSEcCtD
Midodrine—Pain—Sunitinib—pancreatic cancer	0.00231	0.00287	CcSEcCtD
Midodrine—Hypertension—Gemcitabine—pancreatic cancer	0.00229	0.00285	CcSEcCtD
Midodrine—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.00228	0.00283	CcSEcCtD
Midodrine—Asthenia—Tamoxifen—pancreatic cancer	0.00226	0.00281	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00224	0.00279	CcSEcCtD
Midodrine—Confusional state—Irinotecan—pancreatic cancer	0.00224	0.00279	CcSEcCtD
Midodrine—Asthenia—Erlotinib—pancreatic cancer	0.00224	0.00278	CcSEcCtD
Midodrine—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.00223	0.00277	CcSEcCtD
Midodrine—Pruritus—Tamoxifen—pancreatic cancer	0.00223	0.00277	CcSEcCtD
Midodrine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00221	0.00274	CcSEcCtD
Midodrine—Pruritus—Erlotinib—pancreatic cancer	0.00221	0.00274	CcSEcCtD
Midodrine—Nervous system disorder—Irinotecan—pancreatic cancer	0.00218	0.00271	CcSEcCtD
Midodrine—Confusional state—Fluorouracil—pancreatic cancer	0.00215	0.00267	CcSEcCtD
Midodrine—Urinary tract disorder—Docetaxel—pancreatic cancer	0.00214	0.00265	CcSEcCtD
Midodrine—Abdominal pain—Sunitinib—pancreatic cancer	0.00213	0.00265	CcSEcCtD
Midodrine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00212	0.00264	CcSEcCtD
Midodrine—Urethral disorder—Docetaxel—pancreatic cancer	0.00212	0.00263	CcSEcCtD
Midodrine—Skin disorder—Gemcitabine—pancreatic cancer	0.0021	0.00261	CcSEcCtD
Midodrine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00209	0.00259	CcSEcCtD
Midodrine—Dizziness—Tamoxifen—pancreatic cancer	0.00208	0.00259	CcSEcCtD
Midodrine—Tachycardia—Fluorouracil—pancreatic cancer	0.00208	0.00258	CcSEcCtD
Midodrine—Dizziness—Erlotinib—pancreatic cancer	0.00206	0.00256	CcSEcCtD
Midodrine—Erythema multiforme—Docetaxel—pancreatic cancer	0.00205	0.00254	CcSEcCtD
Midodrine—Insomnia—Irinotecan—pancreatic cancer	0.00201	0.0025	CcSEcCtD
Midodrine—Cardiac disorder—Docetaxel—pancreatic cancer	0.00201	0.00249	CcSEcCtD
Midodrine—Flushing—Docetaxel—pancreatic cancer	0.00201	0.00249	CcSEcCtD
Midodrine—Paraesthesia—Irinotecan—pancreatic cancer	0.002	0.00248	CcSEcCtD
Midodrine—Rash—Tamoxifen—pancreatic cancer	0.00199	0.00247	CcSEcCtD
Midodrine—Dermatitis—Tamoxifen—pancreatic cancer	0.00199	0.00247	CcSEcCtD
Midodrine—Dyspnoea—Irinotecan—pancreatic cancer	0.00198	0.00246	CcSEcCtD
Midodrine—Somnolence—Irinotecan—pancreatic cancer	0.00198	0.00246	CcSEcCtD
Midodrine—Headache—Tamoxifen—pancreatic cancer	0.00197	0.00245	CcSEcCtD
Midodrine—Rash—Erlotinib—pancreatic cancer	0.00197	0.00244	CcSEcCtD
Midodrine—Dermatitis—Erlotinib—pancreatic cancer	0.00196	0.00244	CcSEcCtD
Midodrine—Angiopathy—Docetaxel—pancreatic cancer	0.00196	0.00244	CcSEcCtD
Midodrine—Insomnia—Gemcitabine—pancreatic cancer	0.00196	0.00243	CcSEcCtD
Midodrine—Dyspepsia—Irinotecan—pancreatic cancer	0.00196	0.00243	CcSEcCtD
Midodrine—Headache—Erlotinib—pancreatic cancer	0.00195	0.00243	CcSEcCtD
Midodrine—Paraesthesia—Gemcitabine—pancreatic cancer	0.00195	0.00242	CcSEcCtD
Midodrine—Chills—Docetaxel—pancreatic cancer	0.00194	0.00241	CcSEcCtD
Midodrine—Asthenia—Sunitinib—pancreatic cancer	0.00194	0.00241	CcSEcCtD
Midodrine—Dry skin—Epirubicin—pancreatic cancer	0.00193	0.0024	CcSEcCtD
Midodrine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00193	0.0024	CcSEcCtD
Midodrine—Insomnia—Fluorouracil—pancreatic cancer	0.00193	0.00239	CcSEcCtD
Midodrine—Somnolence—Gemcitabine—pancreatic cancer	0.00193	0.00239	CcSEcCtD
Midodrine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00192	0.00239	CcSEcCtD
Midodrine—Paraesthesia—Fluorouracil—pancreatic cancer	0.00191	0.00238	CcSEcCtD
Midodrine—Pruritus—Sunitinib—pancreatic cancer	0.00191	0.00237	CcSEcCtD
Midodrine—Pain—Irinotecan—pancreatic cancer	0.0019	0.00236	CcSEcCtD
Midodrine—Dyspnoea—Fluorouracil—pancreatic cancer	0.0019	0.00236	CcSEcCtD
Midodrine—Mental disorder—Docetaxel—pancreatic cancer	0.0019	0.00235	CcSEcCtD
Midodrine—Somnolence—Fluorouracil—pancreatic cancer	0.00189	0.00235	CcSEcCtD
Midodrine—Dyspepsia—Fluorouracil—pancreatic cancer	0.00187	0.00233	CcSEcCtD
Midodrine—Nausea—Tamoxifen—pancreatic cancer	0.00187	0.00233	CcSEcCtD
Midodrine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00187	0.00232	CcSEcCtD
Midodrine—Pain—Gemcitabine—pancreatic cancer	0.00185	0.0023	CcSEcCtD
Midodrine—Nausea—Erlotinib—pancreatic cancer	0.00185	0.0023	CcSEcCtD
Midodrine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00184	0.00228	CcSEcCtD
Midodrine—Feeling abnormal—Irinotecan—pancreatic cancer	0.00183	0.00228	CcSEcCtD
Midodrine—Back pain—Docetaxel—pancreatic cancer	0.00182	0.00226	CcSEcCtD
Midodrine—Pain—Fluorouracil—pancreatic cancer	0.00182	0.00226	CcSEcCtD
Midodrine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00182	0.00226	CcSEcCtD
Midodrine—Muscle spasms—Docetaxel—pancreatic cancer	0.00181	0.00225	CcSEcCtD
Midodrine—Dry skin—Doxorubicin—pancreatic cancer	0.00179	0.00222	CcSEcCtD
Midodrine—Dizziness—Sunitinib—pancreatic cancer	0.00179	0.00222	CcSEcCtD
Midodrine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00179	0.00222	CcSEcCtD
Midodrine—Abdominal pain—Irinotecan—pancreatic cancer	0.00176	0.00218	CcSEcCtD
Midodrine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00176	0.00218	CcSEcCtD
Midodrine—Dysuria—Epirubicin—pancreatic cancer	0.00171	0.00212	CcSEcCtD
Midodrine—Rash—Sunitinib—pancreatic cancer	0.0017	0.00211	CcSEcCtD
Midodrine—Dermatitis—Sunitinib—pancreatic cancer	0.0017	0.00211	CcSEcCtD
Midodrine—Headache—Sunitinib—pancreatic cancer	0.00169	0.0021	CcSEcCtD
Midodrine—Pollakiuria—Epirubicin—pancreatic cancer	0.00168	0.00209	CcSEcCtD
Midodrine—Hypertension—Docetaxel—pancreatic cancer	0.00163	0.00202	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00161	0.002	CcSEcCtD
Midodrine—Nausea—Sunitinib—pancreatic cancer	0.0016	0.00199	CcSEcCtD
Midodrine—Asthenia—Irinotecan—pancreatic cancer	0.0016	0.00198	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00159	0.00198	CcSEcCtD
Midodrine—Stomatitis—Epirubicin—pancreatic cancer	0.00158	0.00197	CcSEcCtD
Midodrine—Dysuria—Doxorubicin—pancreatic cancer	0.00158	0.00196	CcSEcCtD
Midodrine—Dry mouth—Docetaxel—pancreatic cancer	0.00157	0.00195	CcSEcCtD
Midodrine—Pollakiuria—Doxorubicin—pancreatic cancer	0.00156	0.00194	CcSEcCtD
Midodrine—Asthenia—Gemcitabine—pancreatic cancer	0.00155	0.00193	CcSEcCtD
Midodrine—Confusional state—Docetaxel—pancreatic cancer	0.00155	0.00193	CcSEcCtD
Midodrine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00154	0.00191	CcSEcCtD
Midodrine—Pruritus—Gemcitabine—pancreatic cancer	0.00153	0.0019	CcSEcCtD
Midodrine—Nervous system disorder—Docetaxel—pancreatic cancer	0.00151	0.00187	CcSEcCtD
Midodrine—Pruritus—Fluorouracil—pancreatic cancer	0.00151	0.00187	CcSEcCtD
Midodrine—Tachycardia—Docetaxel—pancreatic cancer	0.0015	0.00186	CcSEcCtD
Midodrine—Skin disorder—Docetaxel—pancreatic cancer	0.00149	0.00185	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00149	0.00185	CcSEcCtD
Midodrine—Bradycardia—Epirubicin—pancreatic cancer	0.00149	0.00185	CcSEcCtD
Midodrine—Dizziness—Irinotecan—pancreatic cancer	0.00147	0.00183	CcSEcCtD
Midodrine—Stomatitis—Doxorubicin—pancreatic cancer	0.00147	0.00182	CcSEcCtD
Midodrine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.00144	0.00179	CcSEcCtD
Midodrine—Urethral disorder—Epirubicin—pancreatic cancer	0.00143	0.00178	CcSEcCtD
Midodrine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00142	0.00177	CcSEcCtD
Midodrine—Dizziness—Fluorouracil—pancreatic cancer	0.00141	0.00175	CcSEcCtD
Midodrine—Rash—Irinotecan—pancreatic cancer	0.0014	0.00174	CcSEcCtD
Midodrine—Dermatitis—Irinotecan—pancreatic cancer	0.0014	0.00174	CcSEcCtD
Midodrine—Headache—Irinotecan—pancreatic cancer	0.00139	0.00173	CcSEcCtD
Midodrine—Insomnia—Docetaxel—pancreatic cancer	0.00139	0.00173	CcSEcCtD
Midodrine—Paraesthesia—Docetaxel—pancreatic cancer	0.00138	0.00171	CcSEcCtD
Midodrine—Erythema multiforme—Epirubicin—pancreatic cancer	0.00138	0.00171	CcSEcCtD
Midodrine—Bradycardia—Doxorubicin—pancreatic cancer	0.00137	0.00171	CcSEcCtD
Midodrine—Dyspnoea—Docetaxel—pancreatic cancer	0.00137	0.0017	CcSEcCtD
Midodrine—Somnolence—Docetaxel—pancreatic cancer	0.00137	0.0017	CcSEcCtD
Midodrine—Rash—Gemcitabine—pancreatic cancer	0.00137	0.0017	CcSEcCtD
Midodrine—Dermatitis—Gemcitabine—pancreatic cancer	0.00136	0.0017	CcSEcCtD
Midodrine—Headache—Gemcitabine—pancreatic cancer	0.00136	0.00169	CcSEcCtD
Midodrine—Cardiac disorder—Epirubicin—pancreatic cancer	0.00135	0.00168	CcSEcCtD
Midodrine—Flushing—Epirubicin—pancreatic cancer	0.00135	0.00168	CcSEcCtD
Midodrine—Dyspepsia—Docetaxel—pancreatic cancer	0.00135	0.00168	CcSEcCtD
Midodrine—Rash—Fluorouracil—pancreatic cancer	0.00134	0.00167	CcSEcCtD
Midodrine—Dermatitis—Fluorouracil—pancreatic cancer	0.00134	0.00167	CcSEcCtD
Midodrine—Headache—Fluorouracil—pancreatic cancer	0.00133	0.00166	CcSEcCtD
Midodrine—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.00133	0.00166	CcSEcCtD
Midodrine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00133	0.00165	CcSEcCtD
Midodrine—Angiopathy—Epirubicin—pancreatic cancer	0.00132	0.00164	CcSEcCtD
Midodrine—Urethral disorder—Doxorubicin—pancreatic cancer	0.00132	0.00164	CcSEcCtD
Midodrine—Nausea—Irinotecan—pancreatic cancer	0.00132	0.00164	CcSEcCtD
Midodrine—Pain—Docetaxel—pancreatic cancer	0.00131	0.00163	CcSEcCtD
Midodrine—Chills—Epirubicin—pancreatic cancer	0.00131	0.00163	CcSEcCtD
Midodrine—Nausea—Gemcitabine—pancreatic cancer	0.00129	0.0016	CcSEcCtD
Midodrine—Mental disorder—Epirubicin—pancreatic cancer	0.00128	0.00159	CcSEcCtD
Midodrine—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00128	0.00159	CcSEcCtD
Midodrine—Feeling abnormal—Docetaxel—pancreatic cancer	0.00127	0.00157	CcSEcCtD
Midodrine—Nausea—Fluorouracil—pancreatic cancer	0.00127	0.00157	CcSEcCtD
Midodrine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00126	0.00156	CcSEcCtD
Midodrine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00125	0.00156	CcSEcCtD
Midodrine—Flushing—Doxorubicin—pancreatic cancer	0.00125	0.00156	CcSEcCtD
Midodrine—Flatulence—Epirubicin—pancreatic cancer	0.00125	0.00156	CcSEcCtD
Midodrine—Tension—Epirubicin—pancreatic cancer	0.00125	0.00155	CcSEcCtD
Midodrine—Nervousness—Epirubicin—pancreatic cancer	0.00123	0.00153	CcSEcCtD
Midodrine—Back pain—Epirubicin—pancreatic cancer	0.00123	0.00153	CcSEcCtD
Midodrine—Angiopathy—Doxorubicin—pancreatic cancer	0.00123	0.00152	CcSEcCtD
Midodrine—Muscle spasms—Epirubicin—pancreatic cancer	0.00122	0.00152	CcSEcCtD
Midodrine—Abdominal pain—Docetaxel—pancreatic cancer	0.00122	0.00151	CcSEcCtD
Midodrine—Chills—Doxorubicin—pancreatic cancer	0.00121	0.00151	CcSEcCtD
Midodrine—Mental disorder—Doxorubicin—pancreatic cancer	0.00118	0.00147	CcSEcCtD
Midodrine—Agitation—Epirubicin—pancreatic cancer	0.00117	0.00145	CcSEcCtD
Midodrine—Flatulence—Doxorubicin—pancreatic cancer	0.00116	0.00144	CcSEcCtD
Midodrine—Tension—Doxorubicin—pancreatic cancer	0.00115	0.00143	CcSEcCtD
Midodrine—Nervousness—Doxorubicin—pancreatic cancer	0.00114	0.00142	CcSEcCtD
Midodrine—Back pain—Doxorubicin—pancreatic cancer	0.00114	0.00141	CcSEcCtD
Midodrine—Muscle spasms—Doxorubicin—pancreatic cancer	0.00113	0.0014	CcSEcCtD
Midodrine—Asthenia—Docetaxel—pancreatic cancer	0.0011	0.00137	CcSEcCtD
Midodrine—Hypertension—Epirubicin—pancreatic cancer	0.0011	0.00136	CcSEcCtD
Midodrine—Pruritus—Docetaxel—pancreatic cancer	0.00109	0.00135	CcSEcCtD
Midodrine—Agitation—Doxorubicin—pancreatic cancer	0.00108	0.00134	CcSEcCtD
Midodrine—Anxiety—Epirubicin—pancreatic cancer	0.00108	0.00134	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00107	0.00133	CcSEcCtD
Midodrine—Dry mouth—Epirubicin—pancreatic cancer	0.00106	0.00131	CcSEcCtD
Midodrine—Confusional state—Epirubicin—pancreatic cancer	0.00105	0.0013	CcSEcCtD
Midodrine—Nervous system disorder—Epirubicin—pancreatic cancer	0.00102	0.00126	CcSEcCtD
Midodrine—Dizziness—Docetaxel—pancreatic cancer	0.00102	0.00126	CcSEcCtD
Midodrine—Hypertension—Doxorubicin—pancreatic cancer	0.00101	0.00126	CcSEcCtD
Midodrine—Tachycardia—Epirubicin—pancreatic cancer	0.00101	0.00126	CcSEcCtD
Midodrine—Skin disorder—Epirubicin—pancreatic cancer	0.00101	0.00125	CcSEcCtD
Midodrine—Anxiety—Doxorubicin—pancreatic cancer	0.000997	0.00124	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000994	0.00123	CcSEcCtD
Midodrine—Dry mouth—Doxorubicin—pancreatic cancer	0.000979	0.00122	CcSEcCtD
Midodrine—Rash—Docetaxel—pancreatic cancer	0.000969	0.0012	CcSEcCtD
Midodrine—Dermatitis—Docetaxel—pancreatic cancer	0.000968	0.0012	CcSEcCtD
Midodrine—Confusional state—Doxorubicin—pancreatic cancer	0.000967	0.0012	CcSEcCtD
Midodrine—Headache—Docetaxel—pancreatic cancer	0.000963	0.0012	CcSEcCtD
Midodrine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000941	0.00117	CcSEcCtD
Midodrine—Insomnia—Epirubicin—pancreatic cancer	0.000938	0.00117	CcSEcCtD
Midodrine—Tachycardia—Doxorubicin—pancreatic cancer	0.000936	0.00116	CcSEcCtD
Midodrine—Skin disorder—Doxorubicin—pancreatic cancer	0.000932	0.00116	CcSEcCtD
Midodrine—Paraesthesia—Epirubicin—pancreatic cancer	0.000931	0.00116	CcSEcCtD
Midodrine—Dyspnoea—Epirubicin—pancreatic cancer	0.000924	0.00115	CcSEcCtD
Midodrine—Somnolence—Epirubicin—pancreatic cancer	0.000922	0.00115	CcSEcCtD
Midodrine—Nausea—Docetaxel—pancreatic cancer	0.000913	0.00113	CcSEcCtD
Midodrine—Dyspepsia—Epirubicin—pancreatic cancer	0.000913	0.00113	CcSEcCtD
Midodrine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000895	0.00111	CcSEcCtD
Midodrine—Pain—Epirubicin—pancreatic cancer	0.000887	0.0011	CcSEcCtD
Midodrine—Insomnia—Doxorubicin—pancreatic cancer	0.000868	0.00108	CcSEcCtD
Midodrine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000862	0.00107	CcSEcCtD
Midodrine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000855	0.00106	CcSEcCtD
Midodrine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000854	0.00106	CcSEcCtD
Midodrine—Somnolence—Doxorubicin—pancreatic cancer	0.000853	0.00106	CcSEcCtD
Midodrine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000848	0.00105	CcSEcCtD
Midodrine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000845	0.00105	CcSEcCtD
Midodrine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000828	0.00103	CcSEcCtD
Midodrine—Pain—Doxorubicin—pancreatic cancer	0.00082	0.00102	CcSEcCtD
Midodrine—Abdominal pain—Epirubicin—pancreatic cancer	0.00082	0.00102	CcSEcCtD
Midodrine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000791	0.000982	CcSEcCtD
Midodrine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000785	0.000975	CcSEcCtD
Midodrine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000758	0.000942	CcSEcCtD
Midodrine—Asthenia—Epirubicin—pancreatic cancer	0.000744	0.000924	CcSEcCtD
Midodrine—Pruritus—Epirubicin—pancreatic cancer	0.000734	0.000911	CcSEcCtD
Midodrine—Asthenia—Doxorubicin—pancreatic cancer	0.000688	0.000855	CcSEcCtD
Midodrine—Dizziness—Epirubicin—pancreatic cancer	0.000686	0.000852	CcSEcCtD
Midodrine—Pruritus—Doxorubicin—pancreatic cancer	0.000679	0.000843	CcSEcCtD
Midodrine—Rash—Epirubicin—pancreatic cancer	0.000654	0.000812	CcSEcCtD
Midodrine—Dermatitis—Epirubicin—pancreatic cancer	0.000653	0.000811	CcSEcCtD
Midodrine—Headache—Epirubicin—pancreatic cancer	0.00065	0.000807	CcSEcCtD
Midodrine—Dizziness—Doxorubicin—pancreatic cancer	0.000634	0.000788	CcSEcCtD
Midodrine—Nausea—Epirubicin—pancreatic cancer	0.000616	0.000765	CcSEcCtD
Midodrine—Rash—Doxorubicin—pancreatic cancer	0.000605	0.000751	CcSEcCtD
Midodrine—Dermatitis—Doxorubicin—pancreatic cancer	0.000604	0.000751	CcSEcCtD
Midodrine—Headache—Doxorubicin—pancreatic cancer	0.000601	0.000747	CcSEcCtD
Midodrine—Nausea—Doxorubicin—pancreatic cancer	0.00057	0.000708	CcSEcCtD
Midodrine—ADRA1B—Signaling by GPCR—CNR1—pancreatic cancer	0.000162	0.000832	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SSTR2—pancreatic cancer	0.000162	0.000831	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000161	0.000826	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NRP1—pancreatic cancer	0.000161	0.000826	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CNR2—pancreatic cancer	0.000161	0.000825	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GLP1R—pancreatic cancer	0.000161	0.000825	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—CXCL8—pancreatic cancer	0.000161	0.000824	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CNR1—pancreatic cancer	0.000159	0.000813	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCKAR—pancreatic cancer	0.000158	0.000811	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—GCG—pancreatic cancer	0.000157	0.000803	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCKBR—pancreatic cancer	0.000156	0.000802	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—SST—pancreatic cancer	0.000156	0.0008	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000156	0.000798	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HEY2—pancreatic cancer	0.000155	0.000795	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000154	0.000788	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—JAG2—pancreatic cancer	0.000153	0.000787	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—GCG—pancreatic cancer	0.000153	0.000786	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GAST—pancreatic cancer	0.000151	0.000777	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MEN1—pancreatic cancer	0.000151	0.000775	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.00015	0.00077	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AGTR1—pancreatic cancer	0.000149	0.000766	CbGpPWpGaD
Midodrine—ADRA1A—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000149	0.000764	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—DTX4—pancreatic cancer	0.000147	0.000754	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GLI1—pancreatic cancer	0.000147	0.000754	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000146	0.000749	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000145	0.000744	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SHH—pancreatic cancer	0.000144	0.00074	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CNR1—pancreatic cancer	0.000144	0.000739	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SCT—pancreatic cancer	0.000144	0.000736	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HEY1—pancreatic cancer	0.000144	0.000736	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH4—pancreatic cancer	0.000143	0.000735	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000143	0.000734	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NRP1—pancreatic cancer	0.000143	0.000734	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IAPP—pancreatic cancer	0.000142	0.000731	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PRSS1—pancreatic cancer	0.000141	0.000721	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—GCG—pancreatic cancer	0.000139	0.000713	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000139	0.000712	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HEY2—pancreatic cancer	0.000138	0.000706	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCK—pancreatic cancer	0.000137	0.000702	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTHLH—pancreatic cancer	0.000137	0.000701	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTCH1—pancreatic cancer	0.000137	0.000701	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GAST—pancreatic cancer	0.000135	0.00069	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CNR2—pancreatic cancer	0.000133	0.000685	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GLP1R—pancreatic cancer	0.000133	0.000685	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—CXCL8—pancreatic cancer	0.000133	0.000684	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000133	0.000684	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AGTR1—pancreatic cancer	0.000133	0.000681	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCKAR—pancreatic cancer	0.000131	0.000673	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SCT—pancreatic cancer	0.000128	0.000654	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HEY1—pancreatic cancer	0.000128	0.000654	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JAG2—pancreatic cancer	0.000127	0.000653	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MEN1—pancreatic cancer	0.000125	0.000644	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SST—pancreatic cancer	0.000125	0.000641	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000123	0.000633	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000123	0.000632	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—JAG1—pancreatic cancer	0.000122	0.000628	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH3—pancreatic cancer	0.000122	0.000625	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ARG2—pancreatic cancer	0.000122	0.000625	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCK—pancreatic cancer	0.000122	0.000624	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SHH—pancreatic cancer	0.00012	0.000614	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH4—pancreatic cancer	0.000119	0.00061	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CNR2—pancreatic cancer	0.000119	0.000608	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GLP1R—pancreatic cancer	0.000119	0.000608	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—CXCL8—pancreatic cancer	0.000118	0.000608	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IAPP—pancreatic cancer	0.000118	0.000606	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCKAR—pancreatic cancer	0.000117	0.000598	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CNR1—pancreatic cancer	0.000115	0.000592	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTHLH—pancreatic cancer	0.000113	0.000582	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTCH1—pancreatic cancer	0.000113	0.000582	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JAG2—pancreatic cancer	0.000113	0.00058	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000112	0.000574	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GCG—pancreatic cancer	0.000111	0.000572	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MEN1—pancreatic cancer	0.000111	0.000572	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000108	0.000556	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TYMP—pancreatic cancer	0.000107	0.000546	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SHH—pancreatic cancer	0.000106	0.000545	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AGTR1—pancreatic cancer	0.000106	0.000545	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH4—pancreatic cancer	0.000106	0.000542	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IAPP—pancreatic cancer	0.000105	0.000539	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STK11—pancreatic cancer	0.000105	0.000537	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SST—pancreatic cancer	0.000104	0.000532	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000102	0.000525	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JAG1—pancreatic cancer	0.000102	0.000521	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH3—pancreatic cancer	0.000101	0.000519	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTHLH—pancreatic cancer	0.000101	0.000517	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTCH1—pancreatic cancer	0.000101	0.000517	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CD—pancreatic cancer	9.85e-05	0.000505	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CNR1—pancreatic cancer	9.58e-05	0.000491	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.45e-05	0.000485	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CG—pancreatic cancer	9.3e-05	0.000477	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GCG—pancreatic cancer	9.25e-05	0.000474	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SST—pancreatic cancer	9.22e-05	0.000473	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SMAD4—pancreatic cancer	9.18e-05	0.000471	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.09e-05	0.000466	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—CXCL8—pancreatic cancer	9.08e-05	0.000466	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JAG1—pancreatic cancer	9.02e-05	0.000463	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CD—pancreatic cancer	9e-05	0.000462	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH3—pancreatic cancer	8.99e-05	0.000461	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HES1—pancreatic cancer	8.96e-05	0.00046	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AGTR1—pancreatic cancer	8.83e-05	0.000453	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STK11—pancreatic cancer	8.7e-05	0.000446	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GLP1R—pancreatic cancer	8.58e-05	0.00044	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CB—pancreatic cancer	8.58e-05	0.00044	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CNR1—pancreatic cancer	8.51e-05	0.000436	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—DPYD—pancreatic cancer	8.45e-05	0.000433	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CG—pancreatic cancer	8.26e-05	0.000424	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL8—pancreatic cancer	8.25e-05	0.000423	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GCG—pancreatic cancer	8.22e-05	0.000421	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CD—pancreatic cancer	8.17e-05	0.000419	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	8.01e-05	0.000411	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.99e-05	0.00041	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TERT—pancreatic cancer	7.85e-05	0.000403	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.84e-05	0.000402	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AGTR1—pancreatic cancer	7.84e-05	0.000402	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STK11—pancreatic cancer	7.73e-05	0.000396	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SMAD4—pancreatic cancer	7.62e-05	0.000391	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL8—pancreatic cancer	7.54e-05	0.000387	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HIF1A—pancreatic cancer	7.51e-05	0.000385	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TSC2—pancreatic cancer	7.49e-05	0.000384	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HES1—pancreatic cancer	7.44e-05	0.000382	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—APOE—pancreatic cancer	7.33e-05	0.000376	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CD—pancreatic cancer	7.26e-05	0.000372	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KDR—pancreatic cancer	7.18e-05	0.000368	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CB—pancreatic cancer	7.12e-05	0.000365	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.97e-05	0.000357	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL8—pancreatic cancer	6.85e-05	0.000351	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NFKBIA—pancreatic cancer	6.83e-05	0.00035	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SMAD4—pancreatic cancer	6.77e-05	0.000347	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH1—pancreatic cancer	6.77e-05	0.000347	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	6.7e-05	0.000343	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CG—pancreatic cancer	6.62e-05	0.000339	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—NRAS—pancreatic cancer	6.62e-05	0.000339	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	6.61e-05	0.000339	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGF—pancreatic cancer	6.54e-05	0.000335	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TERT—pancreatic cancer	6.52e-05	0.000334	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	6.33e-05	0.000325	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HIF1A—pancreatic cancer	6.23e-05	0.00032	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TSC2—pancreatic cancer	6.22e-05	0.000319	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CD44—pancreatic cancer	6.21e-05	0.000318	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—APOE—pancreatic cancer	6.09e-05	0.000312	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	6.08e-05	0.000312	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EGFR—pancreatic cancer	6.03e-05	0.000309	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KDR—pancreatic cancer	5.96e-05	0.000306	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GCG—pancreatic cancer	5.95e-05	0.000305	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CD—pancreatic cancer	5.82e-05	0.000298	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	5.79e-05	0.000297	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.76e-05	0.000295	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—KRAS—pancreatic cancer	5.7e-05	0.000292	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	5.67e-05	0.000291	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	5.62e-05	0.000288	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—STK11—pancreatic cancer	5.59e-05	0.000287	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	5.54e-05	0.000284	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	5.52e-05	0.000283	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	5.49e-05	0.000282	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	5.49e-05	0.000282	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	5.43e-05	0.000278	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	5.41e-05	0.000277	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	5.3e-05	0.000272	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CA—pancreatic cancer	5.23e-05	0.000268	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CB—pancreatic cancer	5.07e-05	0.00026	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	5.04e-05	0.000258	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	5e-05	0.000257	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	4.99e-05	0.000256	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	4.88e-05	0.00025	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	4.88e-05	0.00025	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL8—pancreatic cancer	4.87e-05	0.00025	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—HRAS—pancreatic cancer	4.84e-05	0.000248	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	4.83e-05	0.000248	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	4.82e-05	0.000247	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.81e-05	0.000247	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.78e-05	0.000245	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	4.73e-05	0.000242	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKT1—pancreatic cancer	4.71e-05	0.000241	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CASP3—pancreatic cancer	4.66e-05	0.000239	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCND1—pancreatic cancer	4.54e-05	0.000233	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CTNNB1—pancreatic cancer	4.5e-05	0.000231	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	4.44e-05	0.000228	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP9—pancreatic cancer	4.41e-05	0.000226	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	4.38e-05	0.000225	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	4.34e-05	0.000223	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	4.29e-05	0.00022	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	4.27e-05	0.000219	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.25e-05	0.000218	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	4.21e-05	0.000216	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	4.2e-05	0.000215	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	4.06e-05	0.000208	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	4.04e-05	0.000207	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	4.02e-05	0.000206	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	3.96e-05	0.000203	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	3.92e-05	0.000201	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APOE—pancreatic cancer	3.91e-05	0.000201	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	3.91e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	3.91e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	3.87e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.86e-05	0.000198	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	3.77e-05	0.000193	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	3.74e-05	0.000192	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	3.73e-05	0.000191	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	3.66e-05	0.000188	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	3.64e-05	0.000187	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	3.64e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	3.63e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	3.59e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	3.57e-05	0.000183	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	3.56e-05	0.000183	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	3.55e-05	0.000182	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.53e-05	0.000181	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	3.47e-05	0.000178	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	3.44e-05	0.000176	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.41e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	3.37e-05	0.000173	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	3.36e-05	0.000173	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	3.35e-05	0.000172	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	3.31e-05	0.00017	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	3.28e-05	0.000168	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	3.25e-05	0.000167	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	3.25e-05	0.000167	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	3.24e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	3.23e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	3.15e-05	0.000162	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.11e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	3.09e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	3.02e-05	0.000155	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	3.01e-05	0.000155	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	3e-05	0.000154	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	2.99e-05	0.000153	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	2.96e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.92e-05	0.00015	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.89e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.88e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	2.86e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	2.79e-05	0.000143	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.71e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	2.68e-05	0.000138	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.68e-05	0.000138	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	2.68e-05	0.000137	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	2.63e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.57e-05	0.000132	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	2.53e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	2.48e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.48e-05	0.000127	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	2.37e-05	0.000122	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.34e-05	0.00012	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.28e-05	0.000117	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.2e-05	0.000113	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.11e-05	0.000108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	2.1e-05	0.000107	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.86e-05	9.55e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.65e-05	8.46e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.35e-05	6.91e-05	CbGpPWpGaD
